Pipelines

SH-114

A treatment for Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

DISEASE STATE OVERVIEW

SH-114 is a preferred regimen for both Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in various mono & combination settings.

  • Approximately 10,000 patients in the US are diagnosed with MDS per year1
  • Approximately 20,000 patients in the US are diagnosed with AML per year1

Regulatory Status

Coming soon.

1 American Cancer Society. Cancer Facts & Figures, 2021.